Literature DB >> 18334877

Immune cells in primary gastrointestinal stromal tumors.

Silke Cameron1, Florian Haller, Joszef Dudas, Federico Moriconi, Bastian Gunawan, Thomas Armbrust, Claus Langer, Laszlo Füzesi, Giuliano Ramadori.   

Abstract

INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They are regarded as having relatively uniform histology, although their potential for malignant behavior varies. Despite a strong promoting role of tumor-infiltrating innate immune cells in neoplastic progression, the presence of immune cells in GISTs has not yet been studied.
METHODS: A total of 47 untreated, c-kit-positive primary GISTs were immunohistochemically analyzed to distinguish histiocytic and dendritic cells (DCs) (KIM-1P, fascin, and CD68) from cells of lymphoplasmacellular origin (CD3, CD20, and CD56). Furthermore, the gene expression of proinflammatory cytokines was characterized by real-time, reverse transcription-PCR analysis of total RNA extracted from frozen tissue samples.
RESULTS: KIM-1P+ cells were the dominant immune cells (851+/-295 cells/mm2) and were scattered among the tumor cells. Most of the KIM-1P+ cells showed cellular projections characteristic of DCs. Fascin positivity identified a subgroup of DCs. In comparison to KIM-1P+ cells, there were significantly fewer CD68+ macrophages (196+/-217 cells/mm2). CD3+ T cells were the dominant lymphocytes (201+/-331 cells/mm2), whereas B cells (60+/-126 cells/mm2) were few. On transcriptional level, a concomitant gene expression of cytokines for the classical acute phase cytokines TNF-alpha and IL-6 was missing, thus supporting the rather innate status of immune cells.
CONCLUSION: GISTs contain, beside T lymphocytes, a high number of monocyte-derived cells, which we suggest are, at least in part, immature DCs. Together with the lack of gene expression of inflammatory cytokines in tumor tissue our results point to a possible 'symbiotic relationship' between the tumor and the local immune cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334877     DOI: 10.1097/MEG.0b013e3282f3a403

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  11 in total

1.  [Multilayer analysis of signal transduction and cell cycle control in GIST. Identifying new interaction partners with differential regulation].

Authors:  F Haller; D J Zhang; C Löbke; A von Heydebreck; U Korf; L Füzesi; O Sahin
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  PDL1 expression is an independent prognostic factor in localized GIST.

Authors:  François Bertucci; Pascal Finetti; Emilie Mamessier; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  [Gastrointestinal stromal tumors from the surgical point of view. Laparoscopic therapy].

Authors:  C Langer; P Schüler; H Becker; T Liersch
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

Review 4.  GIST treatment options after tyrosine kinase inhibitors.

Authors:  Natthapol Songdej; Margaret von Mehren
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

6.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

7.  The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.

Authors:  Chaoyong Shen; Luyin Han; Baike Liu; Guixiang Zhang; Zhaolun Cai; Xiaonan Yin; Yuan Yin; Zhixin Chen; Bo Zhang
Journal:  Br J Cancer       Date:  2022-02-08       Impact factor: 9.075

8.  Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

Authors:  Vinod P Balachandran; Michael J Cavnar; Shan Zeng; Zubin M Bamboat; Lee M Ocuin; Hebroon Obaid; Eric C Sorenson; Rachel Popow; Charlotte Ariyan; Ferdinand Rossi; Peter Besmer; Tianhua Guo; Cristina R Antonescu; Takahiro Taguchi; Jianda Yuan; Jedd D Wolchok; James P Allison; Ronald P DeMatteo
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

9.  CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.

Authors:  Alexandre de Nonneville; Pascal Finetti; Maelle Picard; Audrey Monneur; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.639

10.  Natural killer cells in non-hematopoietic malignancies.

Authors:  Mélanie Desbois; Sylvie Rusakiewicz; Clara Locher; Laurence Zitvogel; Nathalie Chaput
Journal:  Front Immunol       Date:  2012-12-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.